App-Quantinova.ai

Four versus six cycles of docetaxel and cyclophosphamide (TC) in early stage hormone positive breast cancer.

Aparna Basu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.

Xavier Pivot - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Efficacy of primary prophylactic GCSF in patients receiving docetaxel based chemotherapy for breast cancer.

Jamal M Zekri - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

PerTe: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer patientsEfficacy and safety of pertuzumab in real life" setting.

Daniela Cianniello - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Cost effectiveness analysis of Oncotype DX testing in patients with synchronous unilateral primary breast cancer.

Melanie Jean Clark - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?

Agnieszka Irena Jagiello-Gruszfeld - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).

Lee Steven Schwartzberg - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Comparative efficacy and acceptability of first-line single-agent chemotherapy in metastatic breast cancer.

Ying Wang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Changes in patient (pt), tumor, and treatment characteristics over time in 1st line (1L) trastuzumab (H) plus taxane (T; paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer (MBC) trials.

Tanja Badovinac Crnjevic - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer.

Jianhua Zhao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Germline sequencing of advanced prostate cancer patients in the BARCODE2 study.

Sarah Benafif - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Docetaxel

Clinical efficacy and safety of apatinib combined with docetaxel in second-line treatment for advanced gastric cancer: A prospective study.

Mudan Yang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in men with metastatic, castration-sensitive prostate cancer (mCPSC) undergoing androgen deprivation therapy (ADT) plus docetaxel (D) chemotherapy.

Louis Everest - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

The clinical outcome of second generation anti-hormonal therapy in patients with metastatic castrate-resistant prostate cancer following CHAARTED regimen.

Jaspreet Chahal - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Docetaxel in hormone-sensitive prostate cancer with low Gleason scores: A meta-analysis of randomized controlled trials.

Omer Dizdar - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).

Christoph W. Reuter - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.

Igal Kushnir - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer.

Megan Veresh Caram - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Clinical utility of androgen-receptor splice variant 7 (AR-V7) determinations in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Danilo Piana - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.

Abhishek Tripathi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Filters

2459 Abstracts